How Higher Revenue And Narrower Losses Will Impact Schrödinger (SDGR) Investors

• Schrödinger reported third quarter 2026 results with sales of US$26.34 million and revenue of US$64.49 million, alongside a quarterly net loss of US$37.71 million and basic and diluted loss per share of US$0.50.
• Over the first nine months of 2026, Schrödinger recorded higher sales and revenue than a year earlier. At the same time, the cumulative net loss and loss per share from continuing operations narrowed, reflecting a combination of growing commercial activity and ongoing cost pressure.
• This analysis examines how Schrödinger's higher year to date revenue, together with a reduced nine month net loss, informs the broader investment narrative.

Compare Schrödinger's earnings story with other research focused opportunities by scanning the 19 high quality undiscovered gems that are still flying under most investors' radar.

Schrödinger Investment Narrative Recap

To be comfortable holding Schrödinger, you need to believe its physics based software and drug discovery engine can turn higher sales and collaboration revenue into a more efficient business over time. The latest quarter shows that tension clearly. Sales and total revenue were higher than a year ago, yet the quarterly net loss and loss per share from continuing operations both widened.

In the near term, the key swing factor is whether management can keep growing the software and discovery pipeline while holding the line on costs. The nine month numbers point to some progress, with revenue ahead of last year and the cumulative net loss and loss per share narrowing. That supports the story, although it does not remove the execution risk around margins and spending.

For catalysts, the most relevant data point right now is the nine month performance to 30 September 2026. Sales reached US$75.71 million and total revenue was US$181.97 million, both above the prior period. At the same time, the net loss over those nine months came in at US$91.76 million compared with US$135.78 million a year earlier, reflecting an improved loss per share from continuing operations of US$1.23 versus US$1.85.

That combination matters because Schrödinger relies on both software and collaboration economics, including milestone and royalty revenue, which can be volatile. Evidence that higher year to date revenue coincided with a reduced cumulative loss supports the idea that cost measures and revenue mix are having an impact, while still leaving clear risk around future demand from pharma and biotech clients and the timing of any larger partnership payouts.

Schrödinger's narrative projects US$356.2 million revenue and US$25.4 million earnings by 2029. This assumes 11.2% yearly revenue growth and an earnings increase of about US$79.7 million from earnings of a US$54.3 million loss today.

Uncover why Schrödinger's fair value indicates a 9% potential downside to its current price, suggesting a valuation premium that may not hold.

Exploring Other Perspectives

One alternate take on Schrödinger focuses on the risk that its push toward hosted software could drag on reported revenue and margins for longer than expected. The most cautious analysts were only penciling in about 2.4% annual revenue growth and roughly US$19.8 million in earnings by 2029. That is a much more pessimistic path than consensus. These forecasts were set before the latest results, so treat them as starting points and explore how your own view might shift after this earnings update.

Explore 3 other Schrödinger fair value estimates, including one that suggests as much as 9% downside from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research.

• A great starting point for your Schrödinger research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Schrödinger. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to evaluate Schrödinger's overall financial health at a glance.

Looking For More Investment Ideas Beyond Schrödinger?

If Schrödinger has sharpened your thinking about risk, reward, and execution, it can be useful to line that view up against other businesses with different balance sheets, income profiles, and cash flow patterns. The Simply Wall St Screener lets you scan for stocks that better match your preferred mix of resilience, value, and income potential.

• If capital preservation comes first for you, start with companies that score well on stability and risk, then review the 31 resilient stocks with low risk scores to see which ones fit that brief.
• For investors who care most about financial strength and staying power, focus on companies with robust cash positions and modest leverage by checking the list of solid balance sheet and fundamentals (24 results) as a filter.
• If you want potential value combined with quality fundamentals, cast a wider net by scanning the 35 high quality undervalued stocks and compare those candidates with what you see in Schrödinger.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com